PharmiWeb Recruiter Blog

London office supports regional client needs and growing local team

• The new Center is focused on outpacing the rising threat of antimicrobial resistance (AMR) and builds on Johnson & Johnson’s longstanding commitment to tackle this challenge
• The Satellite Center in Cape Town is the second site to open in Johnson & Johnson’s network of research collaborations aimed at addressing the world’s most pressing health challenges
• The collaboration between Johnson & Johnson and H3D will help to further expand and strengthen Africa’s scientific capacity as a global hub for discovery research

Cape Town, South Africa, April 25, 2022 – Johnson & Johnson (the Company) today announced the launch of the J&J Satellite Center for Global Health Discovery (Satellite Center) at the Holistic Drug Discovery and Development (H3D) Centre, University of Cape Town, in Cape Town, South Africa. This marks the latest expansion of the J&J Centers for Global Health Discovery (J&J Centers), a global network of research collaborations between the Company and leading research institutions to accelerate translational and discovery research to address some of the world’s most pressing global health challenges. The Satellite Center at H3D will work to drive new solutions to address the present and rising threat of antimicrobial resistance (AMR) with a specific focus on multidrug-resistant Gram-negative bacteria (MDR-GNB).

SAINT CLOUD, Minn. - April 25, 2022 - Microbiologics, the foremost provider of biomaterials and contract microbiology research services, is pleased to announce the acquisition of Cryologics, a leader in cryopreservation of environmental isolates for use as quality control microorganisms. The procurement of Cryologics extends Microbiologics' capacity to serve QC microbiologists dedicated to the safety of pharmaceutical and personal care products.

WILMINGTON, N.C., April 21, 2022 - The PPD clinical research business of Thermo Fisher Scientific was named "Best Contract Research Organization" at the 15^th annual Vaccine Industry Excellence (ViE) Awards during the 2022 World Vaccine Congress, recognizing its success in helping customers develop safe and effective vaccines to improve health and save lives.

$44 million facility increases production of single-use bioprocess containers that are critical to the development of new vaccines and therapies

-- Kite’s Global CAR T-Cell Therapy Manufacturing Network Increasing Capacity by 50% to Meet Patient Demand for New Cancer Therapies

Chicago, IL (April 14, 2022) – Advanced Clinical, a clinical development and strategic resourcing organization, is pleased to announce its continued expansion into Europe with the opening of a new office in Zug, Switzerland.

• Clearance of critical milestone expands capability for production of gene therapies, starting with Zolgensma^®

Basel, April 5, 2022 – Novartis today announced the U.S. Food and Drug Administration (FDA) has granted commercial licensure approval for its Durham, N.C. site, a multi-product gene therapy manufacturing facility. This approval allows the state-of-the-art, 170,000 square-foot facility to make, test and release commercial Zolgensma, as well as produce gene therapy product for current and future clinical trials.

Initial grants of approximately $5 million awarded to local and global nonprofits that support groups and causes disproportionately affected by COVID-19

Paris, April 4, 2022. Sanofi launches today its Diversity, Equity & Inclusion (DE&I) Board, the first-of-its-kind in the pharmaceutical industry to feature outside advisors. Sanofi’s DE&I Board will include three of the most influential voices in the DE&I space as Board members appointed for 3 years: organizational psychologist & best-selling author John Amaechi, award-winning social entrepreneur Caroline Casey, and DE&I pioneer and renowned thought-leader Dr. Rohini Anand.